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The cytoplasmic pattern recognition receptor RIG-I
is activated by viral RNA and induces type I IFN re-
sponses to control viral replication. The cellular
dsRNA binding protein PACT can also activate RIG-
I. To counteract innate antiviral responses, some vi-
ruses, including Ebola virus (EBOV), encode proteins
that antagonize RIG-I signaling. Here, we show that
EBOV VP35 inhibits PACT-induced RIG-I ATPase ac-
tivity in a dose-dependent manner. The interaction of
PACT with RIG-I is disrupted by wild-type VP35, but
not by VP35 mutants that are unable to bind PACT. In
addition, PACT-VP35 interaction impairs the associ-
ation between VP35 and the viral polymerase,
thereby diminishing viral RNA synthesis and modu-
lating EBOV replication. PACT-deficient cells are
defective in IFN induction and are insensitive to
VP35 function. These data support a model in which
the VP35-PACT interaction is mutually antagonistic
and plays a fundamental role in determining the
outcome of EBOV infection.
INTRODUCTION
Ebolaviruses (EBOVs) and marburgviruses (MARVs) are nonseg-
mented negative-sense RNA viruses of the Filoviridae family that
cause severe hemorrhagic fever characterized by uncontrolled
virus replication and excessive inflammation (Feldmann et al.,
2003). The severity of these infections is likely aided by the
potent suppression of innate antiviral immunity by filoviral gene
products including the EBOV VP24 protein, the MARV VP40 pro-
tein, and the filoviral VP35 proteins (Basler and Amarasinghe,
2009).
The VP35 proteins are innate immune antagonists that target
RIG-I-like receptors (RLRs), PKR, and RNA silencing activity74 Cell Host & Microbe 14, 74–84, July 17, 2013 ª2013 Elsevier Inc.(Bale et al., 2012; Basler et al., 2003; Basler et al., 2000; Carde-
nas et al., 2006; Fabozzi et al., 2011; Feng et al., 2007; Haasnoot
et al., 2007; Ramanan et al., 2012; Schu¨mann et al., 2009; Zhu
et al., 2012). RLRs detect viral nucleic acids and signal to induce
an interferon (IFN)-a/b response (Leung et al., 2012). That RLR in-
hibition is particularly important is supported by the observation
that preactivation of RIG-I reduces EBOV titers in cell culture up
to 1000-fold (Spiropoulou et al., 2009). Additionally, EBOVs
possessing mutated VP35s that are unable to disrupt RIG-I inhi-
bition induce IFN-a/b responses during infection and are signif-
icantly attenuated in cell culture and in vivo (Cardenas et al.,
2006; Hartman et al., 2006, 2008a, 2008b; Prins et al., 2010b).
These observations suggest that the suppression of RIG-I is a
critical determinant of virulence.
VP35 likely inhibits the RIG-I pathway at several levels,
including by acting as a decoy substrate for the cellular kinases
IKKε and TBK-1 and through interaction with the SUMOylation
machinery (Chang et al., 2009; Prins et al., 2009). VP35 also
binds to dsRNA (Cardenas et al., 2006; Leung et al., 2009,
2010). Biochemical, structural, and functional studies, including
solved crystal structures EBOV VP35 IFN inhibitory domain (IID)
and MARV IID alone and in complex with dsRNA, correlate VP35
dsRNA binding activity with its IFN-antagonist function (Carde-
nas et al., 2006; Leung et al., 2010; Ramanan et al., 2012).
EBOVVP35 contacts both the dsRNA phosphodiester backbone
and the ends of the dsRNA, forming an ‘‘endcap,’’ while MARV
may not endcap the dsRNA (Bale et al., 2012; Kimberlin et al.,
2010; Leung et al., 2010; Ramanan et al., 2012). Suppression
of virus-induced IFN-a/b gene expression by VP35 proteins is
disrupted by point mutations in the IID that abrogate dsRNA
binding activity (Prins et al., 2010b). Despite these advances,
the precise mechanisms by which VP35 dsRNA binding contrib-
utes to immune suppression and pathogenesis remain incom-
pletely defined.
In addition to its immune antagonist functions, VP35 is also an
essential component of the filovirus polymerase complex. Filovi-
ral mRNA transcription and genome replication require the viral
polymerase complex, which consists of viral proteins NP,
VP35, VP30, and L (Mu¨hlberger et al., 1998). The essential role
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Ebolavirus VP35 Inhibits PACT Activation of RIG-Iof VP35 for viral polymerase activity reflects critical interactions
with both NP and L (Becker et al., 1998; Theriault et al., 2004),
including residues within the VP35 IID (Leung et al., 2010). Little
is known regarding how the immune evasion and RNA replica-
tion functions of VP35 are integrated.
PACT (PKR activator; called PKR-associated protein X [RAX]
inmice) is a double-stranded RNA binding domain (dsRBD)-con-
taining protein that was initially identified as an interacting part-
ner and non-RNA activator of PKR (Ito et al., 1999; Patel and
Sen, 1998; Peters et al., 2001). PACT also interacts with transac-
tivation response RNA-binding protein (TRBP) and together with
TRBP is a binding partner of Dicer (Chendrimada et al., 2005;
Haase et al., 2005; Kok et al., 2007; Lee et al., 2006, 2013). Pre-
vious studies proposed that VP35-PACT interaction may
contribute to VP35 RNA silencing suppressor (RSS) activity
(Fabozzi et al., 2011; Zhu et al., 2012). However, PACT also pro-
motes IFN-a/b responses to viral infection and to dsRNA. This
latter function is mediated through PACT interactions with the
carboxy-terminal domain of RIG-I that stimulates RIG-I ATPase
activity and RIG-I signaling (Iwamura et al., 2001; Kok et al.,
2011). The physiological relevance of this PACT function is sup-
ported by the substantial reduction of IFN-b production in PACT-
depleted cells (Kok et al., 2011).
Here, we demonstrate the functional consequences of VP35-
PACT interaction. RIG-I activation by PACT is inhibited by EBOV
VP35 interaction with PACT. Mutations in the highly conserved
central basic patch within the IID that prevent VP35 binding to
PACT also impair that ability of IID to inhibit RIG-I activation by
PACT. Additionally, VP35-PACT interaction impairs the viral
RNA replication complex, likely through binding to VP35. Finally,
studies performed with recombinant EBOVs possessing wild-
type (WT) or mutated VP35s provide evidence that PACT modu-
lates both host innate response and virus replication in infected
cells.
RESULTS
EBOV VP35 Blocks Activation of RIG-I by PACT
We sought to explore the functional implications of VP35-PACT
interactions in the IFN-a/b response. PACT activation of RIG-I
was confirmed by performing a reporter gene assay for IFN-b
promoter activation; PACT modestly stimulated the IFN-b pro-
moter when coexpressed with RIG-I in the absence of virus
infection. Infection with Sendai virus (SeV) or transfection of
poly(I:C) resulted in a significant stimulation of RIG-I-dependent
responses, as measured by IFN-b promoter activation (Fig-
ure 1A). Expression of VP35 inhibited virus-, poly(I:C)-, and
PACT-induced IFN-b promoter activation (Figure 1A). These re-
sults were confirmed by performing quantitative RT-PCR to
measure the induction of endogenous IFN-b mRNA expression
(Figure 1B) and by bioassay to quantify the release of IFN-a/b
(Figure 1C).
VP35 inhibits virus-induced IFN regulatory factor 3 (IRF-3) acti-
vation (Basler et al., 2000, 2003). As IRF-3 activation is associ-
ated with phosphorylation of serine/threonine residues near its
carboxy terminus (Basler et al., 2003), we monitored the effect
of VP35 on PACT activation of IRF-3 Ser396 phosphorylation.
To facilitate its detection in HEK293T cells, IRF-3 was overex-
pressed. Transfection with RIG-I expression plasmid, or RIG-ICand PACT expression plasmids, induced IRF-3 phosphorylation,
and this phosphorylation was further enhanced by SeV infection
(Figure 1D). VP35 coexpression resulted in a substantial
decrease in IRF-3 phosphorylation in cells expressing both
PACT and RIG-I (Figure 1D). VP35 also inhibited PACT-mediated
activation of the ISG54 promoter (Figure 1E). Cumulatively, these
data demonstrate that VP35 can counter induction of IFN-a/b by
PACT.
The Impact of VP35 on IFNResponses IsMagnified in the
Presence of PACT
Knockdown of PACT decreases the SeV-induced activation of
the IFN-b promoter and impairs cellular antiviral responses
(Kok et al., 2011). Consistent with this, IFN-b promoter activation
was decreased in PACT knockout (KO) MEFs, as compared to
WT MEFs. However, overexpression of PACT augmented the
IFN-b response in the knockout cells in a dose-dependent
manner (Figure 2A). Interestingly, VP35 had little effect on the re-
sidual IFN response in the PACT knockout MEFs but effectively
blocked IFN-b promoter activation in the WT cells. However, re-
constituting PACT in the knockoutMEFs restored VP35 suppres-
sion of IFN-b promoter activation (Figure 2A).
We also generated cell lines that stably express a scrambled,
nontargeting shRNA or a shRNA that targets PACT (Figure 2B).
Cells transfected with the shRNA to PACT mRNA had reduced
PACT expression levels as compared to the scrambled shRNA
cells (Figure 2B). Following SeV infection, a significant decrease
in IFN-b promoter activation was observed in the absence of
PACT in cells transfectedwith either VP35 plasmid or empty vec-
tor, while IFN-b responses were readily detected in the control
knockdown cells (Figure 2B). VP35 readily suppressed IFN-b
promoter activation in the control cells but did not reduce the re-
sidual IFN-b promoter response in PACT knockdown cells (Fig-
ure 2C). These data suggest that PACT is a critical component
of the pathway antagonized by VP35 and that the impact of
VP35 on IFN responses is magnified when PACT is present.
Expression of VP35 Disrupts the Association of PACT
with RIG-I
PACT interacts with RIG-I to augment RIG-I signaling (Kok et al.,
2011). To understand how VP35 interferes with PACT-mediated
RIG-I signaling, we first confirmed VP35-PACT and RIG-I-PACT
interaction by coimmunoprecipitation assay (Figures 3A and 3B).
We further demonstrated that VP35 expression is sufficient to
disrupt the interaction between overexpressed RIG-I and
PACT (Figure 3B). To determine if VP35 expression also affects
the interaction of endogenous PACT with endogenous RIG-I,
we utilized control 293T cells and 293T cells stably expressing
VP35.With anti-PACT antibody in control cells, RIG-I was copre-
cipitated with PACT in the presence or absence of SeV infection.
The strong interaction observed in virus-infected cells correlates
with an increase in RIG-I levels following infection which occurs
even in the VP35-expressing cells. Despite this increase, PACT
andRIG-I did not coprecipitate in the VP35-expressing cells (Fig-
ure 3C), suggesting that VP35 can disrupt the RIG-I-PACT
complex.
To identify the region of VP35 sufficient for interaction with
PACT, we performed domain mapping. We expressed the
VP35 amino terminus (1–218 amino acids) and the carboxyell Host & Microbe 14, 74–84, July 17, 2013 ª2013 Elsevier Inc. 75
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Figure 1. VP35 Inhibits PACT Activation of
RIG-I Signaling
(A) IFN-b promoter reporter gene activity in the
presence of RIG-I, PACT, or VP35 and following
mock transfection, transfection with low-molecu-
lar-weight (LMW) poly(I:C), or infection with Sendai
virus (SeV), as indicated. IFN-b-firefly luciferase
activities were normalized to Renilla luciferase
activity expressed from a cotransfected constitu-
tive expression plasmid. Fold induction was
determined by setting the vector (mock) trans-
fection to a value of 1. The error bars indicate
standard deviation of three independent replicates
(*p < 0.001, **p < 0.001).
(B) Endogenous IFN-bmRNA levels as determined
by quantitative RT-PCR. Transfections were per-
formed as in (A) except that reporter plasmids
were omitted. IFN-bmRNA levels were normalized
to b-actin mRNA levels and are represented as
relative copy number. The data are the average of
three independent experiments, with error bars
representing standard deviation (*p = 0.02, **p =
0.01 by Student’s t test).
(C) An IFN bioassay was performed to assess the
amount of IFN-a/b in cell supernatants. The data in
the chart represent the mean ± SD of three inde-
pendent experiments; *p = 0.02, **p = 0.01, by
Student’s t test.
(D) SeV-induced IRF-3 (S396) phosphorylation in
the presence of transfected empty vector (vector),
RIG-I, PACT, or VP35 expression plasmid with or
without IRF-3 expression plasmid under mock-
infected or SeV-infected conditions. Lysates were
analyzed by western blotting for phospho-S396
IRF-3 (P-IRF-3), total IRF-3, VP35, HA-PACT, and
Flag-RIG-I. Blots are representative of three inde-
pendent experiments.
(E) ISG54 promoter luciferase reporter gene
expression in the presence of RIG-I, PACT, or
VP35. Methods were analogous to those
described in (A), except a reporter plasmid ex-
pressing a firefly luciferase under the control of
tandem ISRE elements from the ISG54 promoter
was used. Fold luciferase activity was determined
relative to the mock-treated, empty vector sam-
ples. The error bars indicate standard deviation
from three independent replicates, *p = 0.007,
**p = 0.01.
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Ebolavirus VP35 Inhibits PACT Activation of RIG-Iterminal IFN inhibitory domain (IID, 215–340 amino acids) (see
Figure S1). By coimmunoprecipitation assay, the IID domain
was sufficient for interaction with PACT (Figure S1).
To determine whether residues that are important for dsRNA
binding are also required to inhibit the activation of RIG-I by
PACT, we tested the activity of K319A/R322A (KRA), R312A,
and F239A mutant VP35 proteins (Cardenas et al., 2006; Leung
et al., 2010). Each mutant failed to coimmunoprecipitate with
PACT (Figure 3D), which correlated with an inability to block
RIG-I-PACT interaction (Figure 3E) and a greatly reduced ability
to inhibit PACT-stimulated activation of the IFN-b promoter (Fig-
ure 3F and Figure S1). Therefore, the ability of VP35 to inhibit
PACT activation of RIG-I signaling requires an intact central
basic patch and endcap residues, which are also important for
dsRNA binding.76 Cell Host & Microbe 14, 74–84, July 17, 2013 ª2013 Elsevier Inc.VP35 IID Can Inhibit Both PACT- and dsRNA-Mediated
RIG-I ATPase Activation
To test the role of PACT in RIG-I activation, we performed in vitro
ATPase assays, which report on RIG-I interactions with activa-
tors such as dsRNA and PACT or inhibitors. In the absence of
activators, RIG-I proteins had negligible intrinsic ATPase activity.
In contrast, the presence of activating ligands such as 8bp
dsRNA or PACT resulted in the activation of RIG-I ATPase activ-
ity of a RIG-I construct lacking the CARD domains and full-length
RIG-I (Figures S2A and S2B).
To test if the RIG-I-activating function localizes to a particular
domain in PACT, we generated PACT truncation mutants con-
sisting of the first two dsRNA binding domains (dsRBD) (PACT
1-2), the third dsRBD (PACT 3), and full-length (PACT 1-2-3)
PACT. In ATPase assays, PACT 1-2 and PACT 3 (Figure S2C)
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Figure 2. PACT Augments the VP35 Inhibi-
tion of IFN-b
(A) IFN-b promoter activation by SeV infection was
assessed by reporter gene assay in WT MEFs, in
PACT knockout (KO) MEFs, or in PACT KO MEFs
transiently transfected with PACT expression
plasmid. The cells were cotransfected with a
constitutive Renilla luciferase reporter gene and
either empty vector (vector) or VP35 expression
plasmid. The firefly luciferase activities were
normalized to Renilla luciferase activities, and the
fold inductions were determined relative to the
mock-treated, empty vector (V) samples. Western
blots for PACT and VP35 are to the right of the
graph. ‘‘#’’ denotes nonspecific band. The bars
depict the standard deviation from three inde-
pendent replicates, *p = 0.0003, **p = 0.04, ***p =
0.006 as determined by Student’s t test.
(B) HEK293T cell lines stably transduced with
either scrambled shRNA (scrambled SH cells) or
PACT shRNA (PACT SH cells) were used for an
IFN-b reporter assay in the presence of trans-
fected empty vector or VP35, following mock
infection or SeV infection. Error bars represent
standard deviation from three independent repli-
cates (*p = 0.004). A western blot for endogenous
PACT is on the right. ‘‘#’’ denotes a nonspecific
band.
(C) The stable HEK293T cell lines expressing either
scrambled shRNA or PACT shRNA were trans-
fected with either empty vector (vector) or VP35
expression plasmid. Eighteen hours post-
transfection, cells were mock infected or infected
with SeV. Relative levels of endogenous IFN-b
mRNA were determined by qRT-PCR. The error
bars represent the standard deviation from three
independent replicates (*p = 0.002).
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Ebolavirus VP35 Inhibits PACT Activation of RIG-Ishowminimal activation of RIG-I, even when used at 5- to10-fold
molar excess compared to PACT 1-2-3 (Figure S2C). Of note,
addition of PACT 1-2 and PACT 3 in trans also did not result in
activation of RIG-I (Figure S2C), suggesting that full-length
PACT, including its linkers, is required for RIG-I activation. Addi-
tion of increasing amounts of PACT 1-2 to full-length PACT
showed a very low level of inhibition at the highest concentration
levels (Figure S2C), suggesting that there may be intermolecular
interactions between the PACT 1-2 and full-length PACT con-
structs, as previously shown (Peters et al., 2001).
VP35 Can Bind to dsRNA and to PACT
To address the relevance of VP35-dsRNA and VP35-PACT inter-
actions for inhibition of RIG-I, we performed ATPase assays in
the presence and absence of dsRNA and in the presence of
increasing concentrations of VP35 IID. The results revealed a
dose-dependent inhibition of RIG-I activation by VP35 (Figures
4A and 4B). This is consistent with our previous studies, whichCell Host & Microbe 14, 7have shown that VP35 IID can bind to
dsRNA and sequester dsRNA from being
recognized by RIG-I (Cardenas et al.,
2006; Leung et al., 2009, 2010). Our
data also suggest that PACT can directly
interact with RIG-I, and that the presenceof VP35 IID disrupts this interaction (Figures 3B and 3C). There-
fore, we tested the ability of VP35 IID to inhibit PACT-mediated
activation of RIG-I. Consistent with our pull-down data, VP35
IID also inhibited PACT-mediated activation of RIG-I ATPase ac-
tivity in a dose-dependent manner (Figures 4C and 4D). We
tested whether PACT activation of RIG-I was an intrinsic prop-
erty of PACT or whether trace levels of dsRNA bound to PACT
were responsible for this activity, as PACT also binds dsRNA.
As shown in Figures 4E and 4F, 8 bp dsRNA or PACT can acti-
vate RIG-I ATPase activity. When the reactions were preincu-
bated with RNase A, the dsRNA-mediated ATPase activation
was completely abrogated, as expected. However, RNase A
addition had no effect on PACT-mediated activation of RIG-I.
Similarly, addition of RNase III did not affect the ability of PACT
to activate RIG-I ATPase activity and had very little effect on
the ability of VP35 IID to inhibit PACT-mediated activation of
RIG-I (Figure S3D) (the difference between lanes 5 and 7 is not
statistically significant: p value is 0.223).4–84, July 17, 2013 ª2013 Elsevier Inc. 77
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Figure 3. Expression of VP35 Disrupts RIG-I-
PACT Interaction
(A) Coimmunoprecipitation of VP35 and PACT.
Cells were transfected PACT and VP35 plasmids,
as indicated. Transfected cell lysates were immu-
noprecipitated (IP) with anti-VP35 antibody, and
VP35, PACT, and b-tubulin were detected by
western blotting.
(B) RIG-I and PACT interaction in the absence or
presence of VP35. A coimmunoprecipitation (coIP)
experiment was performed. VP35, RIG-I, and PACT
were detected by western blotting as indicated.
(C) IP with anti-PACT antibody was performed on
mock or SeV-infected control HEK293T cells or
HEK293T cells stably expressing VP35 (293T-
VP35). The expression of RIG-I and VP35 was de-
tected by western blot.
(D) WT or mutant VP35s, RIG-I, and PACT were
expressed individually or in combination, by tran-
sient transfection, as indicated. A coIP experiment
was performed as above.
(E) WT or mutant VP35s, RIG-I, and PACT were
expressed individually or in combination, as indi-
cated. A coIP experiment was performed as above.
(F) An IFN-b promoter firefly luciferase reporter
assay was performed. The empty vector (vector) or
expression plasmids for RIG-I, PACT, and WT or
mutant VP35 were transfected as indicated. The
cultures were subsequently mock transfected or
transfected with low-molecular-weight (LMW)
poly(I:C). A dual luciferase assay was performed,
and IFN-b firefly luciferase expression activity was
quantified and normalized to control Renilla lucif-
erase activity. Fold induction for the IFN-b
promoter was determined by setting the mock-
treated, empty vector samples to 1. Error bars
indicate standard deviation of three independent
replicates. *p = 0.004, **p = 0.123, ***p = 0.001,
****p = 0.06 (not significant). See also Figure S1.
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Ebolavirus VP35 Inhibits PACT Activation of RIG-INext, we assessed the ability of mutant VP35 IID proteins
which lack the ability to bind dsRNA to inhibit PACT-mediated
activation of RIG-I. While WT VP35 IID can inhibit PACT-medi-
ated RIG-I activation to almost background levels, the mutant
VP35 IID proteins, such as R312A, F239A, and K319A/R322A,
show diminished ability to inhibit PACT-mediated RIG-I activa-
tion (Figure S3E). Together, these data clarify the requirements
for PACT-mediated activation of RIG-I and demonstrate that
VP35 can inhibit the activation of RIG-I by dsRNA and PACT.
PACT Inhibits EBOV RNA Polymerase Activity
VP35 also plays a critical role in viral RNA synthesis (Basler and
Amarasinghe, 2009). VP35 IID contributes to VP35 polymerase
cofactor function, as select mutations in the IID impair viral poly-
merase function (Prins et al., 2010a). We therefore asked
whether PACT affects the participation of VP35 in viral RNA syn-
thesis. PACT was coexpressed with the components of a recon-
stituted viral polymerase complex, and viral RNA synthesis was
assessed by measuring expression of a Renilla luciferase re-
porter gene expressed from a noninfectious, minigenome RNA.78 Cell Host & Microbe 14, 74–84, July 17, 2013 ª2013 Elsevier Inc.PACT expression inhibited the EBOV polymerase complex as
indicated by a dose-dependent reduction in minigenome re-
porter gene expression (Figure 5A, top panel). Representative
western blots indicate that expression levels of NP and VP35
were not affected by PACT overexpression (Figure 5A, bottom
panel). This suggested that PACT has the ability to function as
a restriction factor for EBOV replication, at least when expressed
to sufficient levels. The VP35 central basic patch and endcap
mutants (KRA, R312A, and F239A), which are functional in the
viral minigenome system (Leung et al., 2010), were also tested
for their sensitivity to PACT. In contrast to the results obtained
with WT VP35, these mutants were refractory to inhibition by
PACT (Figure 5B), correlating inhibition with PACT binding to
VP35.
VP35 is an essential component of the EBOV RNA-dependent
RNA polymerase (RdRp) complex because it bridges the enzy-
matic component of the viral RdRp complex, the L protein, and
NP, which associates with the template viral RNA (Becker
et al., 1998). We hypothesized that PACT would disrupt assem-
bly of the RdRp complex through its interaction with VP35. To
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Figure 4. VP35 Inhibition of RIG-I ATPase
Activation Is dsRNA Independent
(A and C) VP35 inhibits activation of RIG-I ATPase
activity by dsRNA (A) and PACT (C) in a concen-
tration-dependent manner.
(B and D) Quantitation of ATPase activity, re-
presented by the amount of inorganic phos-
phate in each lane, was normalized to lane 2.
The data represent the mean, and error bars
indicate the standard deviation. The difference
between the indicated groups was found to sig-
nificant as indicated by *p = 0.0015 (B) and p =
0.0007 (D).
(E) Inhibition of PACT-mediated RIG-I activation
by VP35 is RNA independent. Addition of RNase A
abolishes RIG-I activation by dsRNA (lane 4
versus lane 5), but RNase A has no impact on the
VP35 inhibition of PACT (compare lane 8 versus
lane 9). Free inorganic phosphate levels were
quantified for the region highlighted by the red
dotted box.
(F) Quantitation of relative ATPase activity for
lanes 6–9 normalized to ATPase activity of lane 6.
The difference between the indicated groups was
found to be significant, *p = 0.0054. The data
represent the mean of three independent experi-
ments with the error bars indicating the standard
deviation. See also Figure S2.
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Ebolavirus VP35 Inhibits PACT Activation of RIG-Idetermine if this is the case, VP35 and NP were expressed in
presence or absence of PACT. Immunoprecipitation with an
anti-VP35monoclonal antibody pulled down equivalent amounts
of VP35 in each sample (Figure 5C), and PACT did not detectably
affect the amount of NP that coprecipitated with VP35. To
explore the effect of PACT on association with L, we utilized a
plasmid encoding amino acids 1–505 of L (L505), a region which
was previously shown to be sufficient for interaction with VP35
(Prins et al., 2010a; Trunschke et al., 2013). PACT overexpres-
sion reduced L-VP35 interaction (Figure 5D); however, L interac-
tion with a representative central patch mutant (KRA) was not
affected (Figure S3). Therefore, PACT disruption of VP35-L inter-
action likely accounts for its inhibition of EBOV RNA synthesis as
measured by the minigenome system.
PACT Expression Modulates EBOV Replication and Host
Response
To determine whether PACT exerts its effects in the context of
replicating EBOV, we generated A549 cells stably transducedCell Host & Microbe 14, 7with a PACT-expressing lentivirus or a
control, empty vector lentivirus (Fig-
ure 6A). Both cell lines were infected
(moi = 0.5) with a recombinant WT
EBOV (zEBOV-wt) or a recombinant
EBOV possessing mutations K319A,
R322A, and F239A within the VP35 IID
(zEBOV-VP35 mut). Virus replication
was monitored by plaque assay (Fig-
ure 6B). Overexpression of PACT
reduced infectious zEBOV-wt titers
released into the cell culture medium by15-fold (from 4.5 3 105 to 3 3 104 PFU/mL) by 24 hr postinfec-
tion (Figure 6B). While the titer of zEBOV-wt did not increase
further by 72 hr postinfection in the control cells, virus replica-
tion eventually rose in the PACT cells and reached titers com-
parable to that in the control cells. Interestingly, zEBOV VP35
mut grew in control cells to 100-fold lower levels, as assessed
by plaque assay and qRT-PCR, than did zEBOV-wt (Figure 6B),
but the replication of this mutant virus was not further impaired
by PACT overexpression (Figure 6B). This is in agreement with
the minigenome assays performed with mutant VP35s, where
viral RNA synthesis was not impaired by PACT (Figure 5B).
These data support the hypothesis that PACT can inhibit
EBOV RNA synthesis in a manner that depends upon the pres-
ence of an intact central basic patch to mediate PACT-VP35
interaction.
To determine whether PACT overexpression also modulates
innate immune responses to EBOV infection, we analyzed the
levels of IFN-b and ISG54 by qRT-PCR. IFN-b and ISG54 levels
remained suppressed in zEBOV-wt-infected control cells at4–84, July 17, 2013 ª2013 Elsevier Inc. 79
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Figure 5. PACT Inhibits EBOV RNA Poly-
merase Activity
(A) PACT inhibits EBOV RNA synthesis in a dose-
dependent manner. Increasing amounts of HA-
tagged PACT plasmid (20, 100, 200, 400 ng) were
cotransfected with the plasmids required for
minigenome replication and transcription. Also
cotransfected was a plasmid that expresses
firefly luciferase from an RNA polymerase II pro-
moter. Renilla luciferase activity was normalized
firefly luciferase activity. The error bars indicate
standard deviation of three independent repli-
cates, *p = 0.0008. The western blot shows
expression of NP, VP35, and PACT (HA anti-
body).
(B) A minigenome experiment similar to that
described for (A) was performed except that WT
VP35 or the indicated VP35 mutants were
included and the PACT plasmid amount was kept
constant at 400 ng. The error bars indicate stan-
dard deviation of three independent replicates
(*p = 0.0009).
(C) Effect of PACT on NP-VP35 association. Cells
were transfected with empty vector or plasmids
expressing FLAG-VP35 (VP35), NP, or HA-PACT,
alone or in the indicated combinations. The
lysates were immunoprecipitated with anti-Flag
antibody (VP35) and western blotted for Flag
and NP.
(D) A coIP assay was performed to analyze the
effect of PACT on L-VP35 association. Cells were
transfected with empty vector or plasmids for
VP35, Flag-L1-505 (Flag-L505), or HA-PACT, as
indicated. For immunoprecipitation (IP), anti-
VP35 antibody was used. IP and cell lysates (ly-
sates) were analyzed by western blotting to
detect Flag-L505, HA-PACT, and VP35. See also
Figure S3.
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Ebolavirus VP35 Inhibits PACT Activation of RIG-I24 hpi (Figures 6C and 6D). However, in PACT cells this inhibition
was overcome (Figures 6C and 6D), resulting in about 8-fold
higher levels of IFN-b induction and 20-fold higher ISG54 induc-
tion. By comparison, zEBOV VP35 mut infection resulted in sig-
nificant increase in IFN-b and ISG54 mRNA accumulation in the
PACT-expressing cells, consistent with the RIG-I-activating
nature of PACT and the inability of mutant VP35 to block this acti-
vation (Figures 6C and 6D). These data further support the func-
tional relevance of VP35-PACT interaction in the context of
EBOV infection.
We also infected the PACT knockdown 293T cells and the cor-
responding control stable cell line (Figure S4A) with zEBOV-wt
and zEBOV-VP35 mut at moi = 1 and moi = 0.01. The partial
knockdown did not significantly impact zEBOV-wt growth, as
assessed by measuring infectious viral titers in infected cell me-
dium (moi = 1) (Figure S4B), as might be expected of a virus en-
coding an effective inhibitor of PACT-induced IFN responses.
Interestingly, we also did not see significant restriction of ZE-
BOV-VP35 mut growth, even in the control cells. Nonetheless,
the knockdown cells did display a significant increase viral
RNA synthesis (Figures S4C and S4D) and significantly
decreased IFN-b and ISG54 expression upon zEBOV VP35-
mut infection (Figures S4E and S4F).80 Cell Host & Microbe 14, 74–84, July 17, 2013 ª2013 Elsevier Inc.DISCUSSION
These data represent a uniquemechanismof IFN-antagonism by
a viral protein through direct inhibition of PACT as well as a role
for PACT in inhibition of viral replication. It is notable that VP35
carries out several functions critical to EBOV pathogenesis,
including suppression of IFN-a/b production and assembly of a
functional viral RNA polymerase complex. Although the VP35
C-terminal IID comprises only one-third of VP35, this domain
contributes to several functionally important interactions
including with dsRNA, with NP, and, as shown here, with PACT
and L. Thus, our observations in this study provide a rationale
for the coexistence of IFN-antagonist and RNA replication func-
tions within the same domain of VP35. In this model, filovirus
RNA synthesis, a source of immunostimulatory RNAs, is modu-
lated by VP35 engagement by the RIG-I activator PACT
(Figure 7).
Although PACT interacts with the C terminus of RIG-I, the
structural and biochemical basis by which it modulates RIG-I
activation remains incompletely understood. Our data suggest
that VP35 can interact directly with PACT and thereby prevent
PACT interaction with and activation of RIG-I. Notably, PACT in-
teracts in a context-dependent fashion with multiple cellular
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Figure 6. PACT Expression Inhibits Replica-
tion and Modulates Innate Immune Re-
sponses during EBOV Infection
(A) Western blot for PACT in the control and stable
PACT expressing (PACT) cell lines. # denotes a
nonspecific band.
(B) The cells were infected with zEBOV-wt or zE-
BOV-VP35 mut at moi = 0.5. The supernatants
from infected cells were collected. The virus titers
in 24 and 72 hr postinfection supernatants were
determined by plaque assay. (*p = 0.014).
(C and D) Quantitative RT-PCR for endogenous (C)
IFN-b and (D) ISG54 mRNA levels normalized to
b-actinmRNA at 24 hr postinfection. The error bars
indicate the standard deviation of three replicates
of the RT-PCR reaction. The induction of IFN-b
and ISG54 was found to be significant in PACT
cells compared to control cells for virus infection,
where *p = 0.01 and **p = 0.03 for (C) and *p =
0.003 and **p = 0.03 for (D). See also Figure S4.
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Ebolavirus VP35 Inhibits PACT Activation of RIG-Ibinding partners, reflecting its multifunctional nature. Among
these, PACT interacts with TRBP and Dicer, components of
the RNA-induced silencing complex (RISC), and stimulates the
function of Dicer (Kok et al., 2007; Lee et al., 2006). PACT is
also a dsRNA-binding protein but can activate PKR through pro-
tein-protein interactions between the dsRBDs present in each
protein (Li et al., 2006; Patel and Sen, 1998; Peters et al.,
2001). Evidence suggests that PACT can be phosphorylated
and activated in response to cell stresses, relieving it from inter-
action with TRBP and allowing it to bind to and activate PKR (Pa-
tel et al., 2000; Peters et al., 2006; Singh et al., 2011). Given that
PACT activates PKR and that VP35 inhibits PKR, it will be of in-
terest to determine whether VP35-PACT interaction also contrib-
utes to VP35-PKR inhibition (Fabozzi et al., 2011; Feng et al.,
2007; Schu¨mann et al., 2009; Zhu et al., 2012).
Previous biochemical and structural studies demonstrated
that VP35 interacts with dsRNA via the IID (Kimberlin et al.,
2010; Leung et al., 2009, 2010). Within the VP35 IID structure,
central basic patch residues contact the dsRNA phosphodiester
backbone, while a hydrophobic pocket, which includes residue
F239, binds the ends of the dsRNA, forming an endcap (Kimber-
lin et al., 2010; Leung et al., 2010). Central basic patch residues
also made inter-IID contacts in the structure, highlighting their
additional role in protein-protein interactions (Kimberlin et al.,
2010; Leung et al., 2010). Central basic patch mutations abro-
gated the interaction with PACT in transfected cells and inhibited
its RIG-I stimulatory activity. These data, however, cannot distin-Cell Host & Microbe 14, 7guish whether loss of interaction and inhi-
bition is dependent on or independent of
dsRNA. In vitro assays, in which purified
IID, PACT, and RIG-I were employed,
demonstrated that IID-mediated inhibi-
tion occurs in the absence of added
dsRNA and that it is not affected by addi-
tion of RNase A, suggesting that inhibition
is RNA independent and that IID-PACT
interaction does not require RNA. It re-
mains possible that dsRNA can augment
the VP35-PACT interaction.The IID contributes to interactions necessary for functioning of
the EBOV RNA polymerase (Leung et al., 2010; Prins et al.,
2010a). In our studies, PACT clearly inhibits WT EBOV RNA syn-
thesis. This was evidenced by the fact that PACT is able to inhibit
minigenome activity in a dose-dependentmanner and by the fact
that inhibition was seen when using WT but not mutant VP35s.
Similarly, we detected reduced accumulation of viral mRNA
and genomic RNA in cells infected with WT recombinant
EBOV, but not with an EBOV encoding a mutant VP35. These
data strongly suggest that PACT mediates its inhibitory effects
through interaction with the VP35 IID. Residues of the IID first
basic patch were previously shown to affect VP35 interaction
with NP and thereby disrupt function in the minigenome assay
(Prins et al., 2010a), and interaction of VP35 with NP can be
affected by VP35 interaction with another cellular protein that
binds dsRNA, DRBP76 (Shabman et al., 2011). In contrast, our
coprecipitation assays did not demonstrate any effect of PACT
on VP35-NP interaction. Instead, we demonstrated a dose-
dependent disruption of VP35-L interaction. Although previous
studies on MARV VP35 demonstrated a critical role for a
coiled-coil domain located within the VP35 N-terminal half for
interaction with L (Becker et al., 1998), our data demonstrate
that the VP35 IID is also involved in interaction with L.
The data above support the view that the levels of PACT pre-
sent in EBOV-infected cells can influence both virus replication
and host IFN responses. While the impact of PACT observed
here on viral RNA synthesis and production of infectious viral4–84, July 17, 2013 ª2013 Elsevier Inc. 81
Figure 7. Working Model for Mutual Antagonism between VP35 and
PACT
EBOV VP35 functions as an inhibitor of RIG-I signaling and as an essential
component of the viral RNA replication complex. VP35 can block either the
RNA- or the PACT-mediated activation of RIG-I, but PACT can inhibit the RNA
replication complex through interaction with VP35. Under conditions in which
VP35 levels may be limited, PACT interaction with VP35 may slow virus
replication, resulting in decreased production of immunostimulatory viral
replication products. This would allow VP35 to sense the immune status
through PACT availability and thereby regulate replication accordingly.
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Ebolavirus VP35 Inhibits PACT Activation of RIG-Iparticles is modest, this may not be surprising, given that filovi-
ruses can replicate with high efficiency in human and nonhuman
primate cells and encode multiple mechanisms to counteract
IFN responses. Nonetheless, our observations support a model
in which PACT can impair viral RNA synthesis. This represents a
cell-intrinsic antiviral mechanism for PACT. The combined anti-
viral effects of many IFN-induced genes/host factors are often
greater than the individual impact, and therefore it is likely that
the cumulative effect of multiple IFN-induced and cell intrinsic
host factors, including those identified here for PACT, are likely
to produce a potent antiviral response (Schoggins and Rice,
2011). Therefore we expect that while PACT itself may not effec-
tively control virus replication, the antiviral impact of PACTmight
be greater in combination with other factors or in the absence of
effective PACT inhibitors. Understanding the exact role of PACT,
its interaction(s) with other cellular factors, and its interference
with viral replication processes may lead to antiviral strategies.
EXPERIMENTAL PROCEDURES
Cell Lines and Viruses
Vero, HEK293T, A549, and mouse embryo fibroblast cells were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine82 Cell Host & Microbe 14, 74–84, July 17, 2013 ª2013 Elsevier Inc.serum (FBS), 1% penicillin, and streptomycin (100 unit/ml) (Invitrogen) and
were grown at 37C and 5% CO2. BSRT7 cells were grown in the same me-
dium supplemented with 1% of G418 (50 mg/ml). The PACTWT and knockout
mouse embryo fibroblasts were kindly provided by Dr. Ganes Sen (Lerner
Research Institute, Cleveland Clinic). Sendai virus (SeV) strain Cantell stocks
were prepared by growth in 10-day-old embryonated chicken eggs for
2 days at 37C.
Stable cell lines overexpressing PACT or VP35 were generated using repli-
cation-defective lentiviruses derived from the plasmid pCSIGW. This plasmid
was a gift from Drs. Lubbertus Mudler and Viviana Simon (Icahn School of
Medicine at Mount Sinai).
Short hairpin (sh) PACT knockdown cell lines were generated by using con-
structs based on the retroviral silencing plasmid (pGFP-V-RS shRNA vector)
(OriGene) which contains a CMV promoter-driven tGFP gene, a puromycin
resistance selection, and 29-mer shRNA construct to target PACT (CACCTT
CAGAGTAACCGTTGGTGACATAA) or a control shRNA that consists of an
on-silencing scrambled sequence (50- GCACTACCAGAGCTAACTCAGATAG
TACT-30). The PACT knockdown and control cells were selected following
transfection with puromycin.
Generation of Recombinant EBOV
Starting with a full-length cDNA clone encoding WT Zaire EBOV strain
Mayinga-76, we introduced nucleotide substitutions resulting in three amino
acid changes at VP35 amino acids 239, 319, and 322 (F239A/K319A/R322A)
to generate the virus referred to as zEBOV-VP35 mut. Established procedures
were used to recover the recombinant virus (see the Supplemental Experi-
mental Procedures for details) (Ebihara et al., 2006). After transfection super-
natants were passaged on Vero cells, the first-passage supernatants were
collected at 12 days postinfection, and RNA was extracted using the QIAamp
Viral RNA mini kit (QIAGEN). Complete sequencing of the rescued EBOV was
performed. Virus infectivity titers (focus-forming units, FFUs) were determined
by counting the number of infected cell foci using an indirect immunofluores-
cent antibody assay (Ebihara et al., 2006). Generation of recombinant zEBOV
was carried out in the biosafety level 4 (BSL-4) facilities at Rocky Mountain
Laboratories (NIAID, NIH), and sample inactivation/removal was performed
according to standard operating protocols approved by the local Institutional
Biosafety Committee.
EBOV Infections and RNA Isolation
The following infections were performed under BSL-4 conditions at the Gal-
veston National Laboratory. A549 cells expressing GFP (control) or PACT
were infected (moi = 0.5), and also stable 293T cells, with scrambled or
PACT knockdown, were infected (moi = 0.1 and 1) with either WT Zaire
EBOV (zEBOV-wt) or zEBOV-VP35 mut viruses. At 24 and 72 hr postinfection
(hpi), viral supernatants were collected and clarified by centrifugation, and Tri-
zol (Life Technologies) cell extracts were collected. The resulting viral RNAs
were quantified by real-time PCR (RT-PCR) using OneStep RT-PCR kits
(QIAGEN) (see the Supplemental Experimental Procedures for details).
EBOV Minigenome Assay
The EBOV minigenome assay was based on a previously described system
and was performed in BSRT7 cells (Mu¨hlberger et al., 1999). Details are pro-
vided in the Supplemental Experimental Procedures.
IFN-b and ISG54 Promoter Reporter Gene Assays
HEK293T cells were transfected by using Lipofectamine 2000 (Invitrogen) with
the indicated expression plasmids, an ISG54-promoter or an IFN-b-promoter
firefly luciferase reporter plasmid (100 ng), and a constitutively expressed Re-
nilla luciferase reporter plasmid, pRLTK (10 ng). At 18 hr posttransfection (hpt),
IFN responses were induced as described in the Results. Sixteen hours later,
the cell lysates were assayed with the Dual Luciferase reporter assay (Prom-
ega), and firefly luciferase activity was normalized to Renilla luciferase activity.
IRF-3 Activation Assay
293T cells were transfected with empty vector or with plasmids expressing
RIG-I, PACT or both, with or without plasmids encoding VP35 and/or IRF-3.
Eighteen hours posttransfection, the cells were either mock infected or in-
fected with SeV for 1 hr. Sixteen hours later, cells were lysed with NP-40 lysis
Cell Host & Microbe
Ebolavirus VP35 Inhibits PACT Activation of RIG-Ibuffer (10 mM Tris-HCL [pH 7.4], 100 mM sodium chloride, 1 mM EGTA, 1 mM
EDTA, glycerol, 0.5% NP-40). The lysates were analyzed by western blotting
with anti-phospho-IRF-3 (S396), anti-IRF-3 (total IRF-3), anti-FLAG, anti-HA,
and anti-VP35 antibodies.
Quantitative RT-PCR
Viral RNAs were extracted from infected cells with TRIZOL reagent (Sigma)
and quantified by RT-PCR (see the Supplemental Experimental Procedures
for details).
IFN Bioassay
IFN bioassays were performed as previously described (Leung et al., 2011).
Immunoprecipitation and Western Blotting
Immunoprecipitations were performed in NP-40 lysis buffer using antibodies
described in the Supplemental Experimental Procedures.
Cloning, Protein Expression, and Purification of Proteins for
Biochemical Assays
The coding regions for EBOV VP35 IID (residues 215–340), full-length human
RIG-I (residues 1–925), RIG-I DCARDs (residues 230–925) and human PACT
(residues 1–313), PACT 1-2 (residues 1–193), and PACT 3 (residues 194–
313) were subcloned into a modified pET15b vector and expressed as previ-
ously described (Ramanan et al., 2012).
ATPase Assays
Thin-layer chromatography assays were performed to assess the ATPase ac-
tivity of RIG-I constructs in a reaction containing 10 mM HEPES (pH 7.0),
150 mM NaCl, 1 mM MgCl2, 2 mM TCEP, 100 mM ATP, 5 mCi g-
32P-ATP,
and 100 nM RIG-I DCARDs or 2 mM MBP-RIG-I full-length. Sixty nanomolar
8 bp dsRNA (IDT) with a palindromic sequence (rCrGrCrArUrGrCrG) or
0.7 mM of MBP-PACT full-length was used to activate RIG-I ATPase activity.
VP35 IID constructs (WT or mutants) were added at various concentrations
ranging from 5 to 100 mM. ATPase activity was monitored as previously
described (Ramanan et al., 2012). Some assays were carried out in the pres-
ence of RNase III or RNase A in order to test RNA-independent PACT-VP35
interactions.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
at http://dx.doi.org/10.1016/j.chom.2013.06.010.
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